Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line

被引:55
作者
Zeng, HY
Datta, K
Neid, M
Li, JP
Parangi, S
Mukhopadhyay, D
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA 02215 USA
[3] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA
关键词
D O I
10.1016/S0006-291X(03)00107-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several oncogenes and growth factors are found to be mutated and overexpressed in adenocarcinoma of the pancreas, and may correlate with its highly aggressive nature. Insulin-like growth factor (IGF-I) and its receptor (IGF-IR) are highly expressed in this tumor type. We examined the IGF-IR-mediated signaling pathways in relation to cell proliferation, invasiveness, and expression pattern of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) in the pancreatic cancer line ASPC-1. Our findings show that IGF-IR is an important growth factor receptor for cell proliferation and invasion, and VPF/VEGF expression in ASPC-1. Further experiments indicate that IGF-IR mediates different signaling pathways to execute its functions. Activation of Ras by IGF-IR was found to be required for the cell invasion. On the other hand Src activation through IGF-IR is required for the cell proliferation, invasion, and also VPF/VEGF expression. Taken together, our data indicate the importance of IGF-IR in growth and invasiveness of the pancreatic cancer cell lines and also point out the multiple signaling pathways channeled through this receptor. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:46 / 55
页数:10
相关论文
共 62 条
[1]  
[Anonymous], 1997, BIOCH BIOPHYSICA ACT
[2]   ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER [J].
BARTON, CM ;
STADDON, SL ;
HUGHES, CM ;
HALL, PA ;
OSULLIVAN, C ;
KLOPPEL, G ;
THEIS, B ;
RUSSELL, RCG ;
NEOPTOLEMOS, J ;
WILLIAMSON, RCN ;
LANE, DP ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1076-1082
[3]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[4]  
BERGMANN U, 1995, CANCER RES, V55, P2007
[5]  
Bouterfa HL, 2000, ANTICANCER RES, V20, P2761
[6]   Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon [J].
Cheung, N ;
Wong, MP ;
Yuen, ST ;
Leung, SY ;
Chung, LP .
HUMAN PATHOLOGY, 1998, 29 (09) :910-914
[7]  
Clark JW, 1996, INT J CANCER, V65, P186
[8]   VASCULAR-PERMEABILITY FACTOR - A TUMOR-DERIVED POLYPEPTIDE THAT INDUCES ENDOTHELIAL-CELL AND MONOCYTE PROCOAGULANT ACTIVITY, AND PROMOTES MONOCYTE MIGRATION [J].
CLAUSS, M ;
GERLACH, M ;
GERLACH, H ;
BRETT, J ;
WANG, F ;
FAMILLETTI, PC ;
PAN, YCE ;
OLANDER, JV ;
CONNOLLY, DT ;
STERN, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1535-1545
[9]   TUMOR VASCULAR-PERMEABILITY FACTOR STIMULATES ENDOTHELIAL-CELL GROWTH AND ANGIOGENESIS [J].
CONNOLLY, DT ;
HEUVELMAN, DM ;
NELSON, R ;
OLANDER, JV ;
EPPLEY, BL ;
DELFINO, JJ ;
SIEGEL, NR ;
LEIMGRUBER, RM ;
FEDER, J .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (05) :1470-1478
[10]  
Coppola D, 2000, Cancer Control, V7, P421